Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeonMind Biosciences
Vancouver, British Columbia, Canadaneonmindbiosciences.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
NeonMind Biosciences is developing two psilocybin-based small-molecule drug candidates for obesity (NEO-001 targeting 5-HT2A and NEO-002 targeting 5-HT2C) at the preclinical/pre-IND stage, alongside early-stage clinical service offerings via planned specialty mental health clinics using psychedelic and ketamine-assisted therapies.[1][2][4][6][10].
- Therapeutic areas
- PsychiatryEndocrinology
- Modalities
- Small moleculePeptidesPsychedelic therapyNon-pharmacological therapy
- Industry
- Biotech
02
Partnerships
SRx Health SolutionsBioScript Solutions
Beyond the preview
Go deeper on NeonMind Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeonMind Biosciences.